Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
10-hydroxycamptothecin + Bendamustine hydrochloride
|
DCNYJIL
|
10-hydroxycamptothecin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
10-hydroxycamptothecin + Bendamustine hydrochloride
|
DCQI67T
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
10-hydroxycamptothecin + Bendamustine hydrochloride
|
DC8EB5I
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
10-hydroxycamptothecin + Bendamustine hydrochloride
|
DC8O1K0
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
10-hydroxycamptothecin + Bendamustine hydrochloride
|
DCDF2GH
|
10-hydroxycamptothecin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCHCLB1
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCXSJSM
|
ABIRATERONE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCSHW7D
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCCXZ32
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCMJWP0
|
ABIRATERONE
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCO0EXY
|
ABIRATERONE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DC6LR8H
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCKRQU7
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCDIWR7
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCGV9FW
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCKV1IP
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCCJYNP
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCKY211
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DC11VK3
|
ABIRATERONE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCBJCN0
|
ABIRATERONE
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DC9MRLN
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DCOIL69
|
ABIRATERONE
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DC4RKBX
|
ABIRATERONE
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
ABIRATERONE + Bendamustine hydrochloride
|
DC2YDX0
|
ABIRATERONE
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Amonafide + Bendamustine hydrochloride
|
DCCBITS
|
Amonafide
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCTMDM4
|
Amonafide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DC57505
|
Amonafide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCMSDM9
|
Amonafide
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCNM37B
|
Amonafide
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DC87KOH
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DC3V0KS
|
Amonafide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCL08FE
|
Amonafide
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCW4XC5
|
Amonafide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCIZEEZ
|
Amonafide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCTNOYZ
|
Amonafide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DC1GN3O
|
Amonafide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DC3KSIT
|
Amonafide
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCEBHRJ
|
Amonafide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DCU8B96
|
Amonafide
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Amonafide + Bendamustine hydrochloride
|
DC5J4FQ
|
Amonafide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Anastrozole + Bendamustine hydrochloride
|
DC15ILZ
|
Anastrozole
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCPI3WR
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCQGTDF
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCX1RMQ
|
Anastrozole
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DC6N1AK
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCAITIA
|
Anastrozole
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCRBZ2B
|
Anastrozole
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCDJ78X
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCTDZL4
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCLNNMV
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCZYXH8
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCHPK19
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DC6QGB9
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DC5IV5T
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCMQD61
|
Anastrozole
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCUAJAW
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCI34T2
|
Anastrozole
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCJPU3I
|
Anastrozole
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCG4XNP
|
Anastrozole
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DC6RAH5
|
Anastrozole
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCE8IGO
|
Anastrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DC3HPJB
|
Anastrozole
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Anastrozole + Bendamustine hydrochloride
|
DCV9UA7
|
Anastrozole
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Anastrozole + Bendamustine hydrochloride
|
DCI4LEC
|
Anastrozole
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Anastrozole + Bendamustine hydrochloride
|
DCPMULY
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Arfolitixorin + Bendamustine hydrochloride
|
DCLRDGH
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Arfolitixorin + Bendamustine hydrochloride
|
DC3NP2P
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Arfolitixorin + Bendamustine hydrochloride
|
DCAI1LB
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Arfolitixorin + Bendamustine hydrochloride
|
DCUGH33
|
Arfolitixorin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Arfolitixorin + Bendamustine hydrochloride
|
DCJWKVZ
|
Arfolitixorin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Arfolitixorin + Bendamustine hydrochloride
|
DCZ8CMJ
|
Arfolitixorin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Azacitidine + Bendamustine hydrochloride
|
DCVUTEC
|
Azacitidine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Azacitidine + Bendamustine hydrochloride
|
DC78Q5W
|
Azacitidine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Azacitidine + Bendamustine hydrochloride
|
DCM4UM5
|
Azacitidine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Azacitidine + Bendamustine hydrochloride
|
DCA349R
|
Azacitidine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Bendamustine hydrochloride + Ixabepilone
|
DC68AZF
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Bendamustine hydrochloride + Ixabepilone
|
DCN8MWL
|
Ixabepilone
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Bendamustine hydrochloride + Cyclophosphamide
|
DCVMRUX
|
Cyclophosphamide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Bendamustine hydrochloride + Cyclophosphamide
|
DC3AO5V
|
Cyclophosphamide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Bendamustine hydrochloride + Isoniazid
|
DC65HIV
|
Isoniazid
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Bendamustine hydrochloride + Isoniazid
|
DCXBJNH
|
Isoniazid
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Isoniazid
|
DCGOZOI
|
Isoniazid
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Bendamustine hydrochloride + Isoniazid
|
DCSJ91U
|
Isoniazid
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Bendamustine hydrochloride + Arsenic trioxide
|
DCME8PC
|
Arsenic trioxide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Topetecan
|
DCKQPS6
|
Topetecan
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Ifosfamide
|
DCRD57M
|
Ifosfamide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Bendamustine hydrochloride + Altretamine
|
DC5PPGG
|
Altretamine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Bendamustine hydrochloride + Altretamine
|
DCNY3CI
|
Altretamine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Altretamine
|
DCED36L
|
Altretamine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Bendamustine hydrochloride + Cisplatin
|
DC56382
|
Cisplatin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCNK532
|
Chlorambucil
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Bendamustine hydrochloride + Chlorambucil
|
DC3FG6G
|
Chlorambucil
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Bendamustine hydrochloride + Chlorambucil
|
DC7YU36
|
Chlorambucil
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Bendamustine hydrochloride + ER819762
|
DCN133M
|
ER819762
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Bendamustine hydrochloride + ER819762
|
DC1RSOU
|
ER819762
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Bendamustine hydrochloride + ER819762
|
DC4R46M
|
ER819762
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Bendamustine hydrochloride + ER819762
|
DCUH8YL
|
ER819762
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + ER819762
|
DCOUJG7
|
ER819762
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Bendamustine hydrochloride + ER819762
|
DCEHLPP
|
ER819762
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Bendamustine hydrochloride + Aminolevulinic Acid Hydrochloride
|
DCSHORZ
|
Aminolevulinic Acid Hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Cyclophosphamide
|
DCF4MVO
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Bendamustine hydrochloride + Isoniazid
|
DC8TEP0
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Bendamustine hydrochloride + Isoniazid
|
DCLY4O5
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Bendamustine hydrochloride + Ifosfamide
|
DC2UD5R
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Bendamustine hydrochloride + Ifosfamide
|
DCJ3BJT
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Bendamustine hydrochloride + Altretamine
|
DCIV6WD
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Bendamustine hydrochloride + Altretamine
|
DCD24S2
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Bendamustine hydrochloride + Bortezomib
|
DCT0J5Q
|
Bortezomib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Bendamustine hydrochloride + Bortezomib
|
DCSZ0OK
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Bendamustine hydrochloride + Chlorambucil
|
DC3IQPK
|
Chlorambucil
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Bendamustine hydrochloride + ER819762
|
DCD4Z31
|
ER819762
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Bendamustine hydrochloride + ER819762
|
DCVJ3CY
|
ER819762
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Bendamustine hydrochloride + Pomalidomide
|
DCGI743
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Bendamustine hydrochloride + Ruxolitinib
|
DCHA24S
|
Ruxolitinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
Bendamustine hydrochloride + Ixabepilone
|
DC10RXO
|
Ixabepilone
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Bendamustine hydrochloride + Ixabepilone
|
DCE24JF
|
Ixabepilone
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Bendamustine hydrochloride + Ixabepilone
|
DCTKDUR
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + Ixabepilone
|
DCGN4N1
|
Ixabepilone
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Bendamustine hydrochloride + Isoniazid
|
DC37YIP
|
Isoniazid
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Bendamustine hydrochloride + Isoniazid
|
DCEMLJ3
|
Isoniazid
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bendamustine hydrochloride + Isoniazid
|
DCN2ZBM
|
Isoniazid
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + Isoniazid
|
DCVSL3P
|
Isoniazid
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bendamustine hydrochloride + Isoniazid
|
DC7KW8V
|
Isoniazid
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Bendamustine hydrochloride + Arsenic trioxide
|
DCSMLF8
|
Arsenic trioxide
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Bendamustine hydrochloride + Topetecan
|
DCAB9CV
|
Topetecan
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + Ifosfamide
|
DCNGGM8
|
Ifosfamide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + Ifosfamide
|
DCPAVBZ
|
Ifosfamide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bendamustine hydrochloride + Ifosfamide
|
DCNYAPN
|
Ifosfamide
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Bendamustine hydrochloride + Ifosfamide
|
DCZJZHL
|
Ifosfamide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Bendamustine hydrochloride + Altretamine
|
DCC7TGV
|
Altretamine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Bendamustine hydrochloride + Altretamine
|
DC8VQ0A
|
Altretamine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + Altretamine
|
DCWGPP4
|
Altretamine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bendamustine hydrochloride + Altretamine
|
DCM8JHG
|
Altretamine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Bendamustine hydrochloride + Altretamine
|
DC369TI
|
Altretamine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Bendamustine hydrochloride + Altretamine
|
DC38MOU
|
Altretamine
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Bendamustine hydrochloride + Bortezomib
|
DCKJVSO
|
Bortezomib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bendamustine hydrochloride + Cisplatin
|
DC1XR12
|
Cisplatin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Bendamustine hydrochloride + Cisplatin
|
DCY5UAQ
|
Cisplatin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Bendamustine hydrochloride + Cisplatin
|
DC97QKM
|
Cisplatin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCO57MN
|
Chlorambucil
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCG1O4R
|
Chlorambucil
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCL08C1
|
Chlorambucil
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCBYKFW
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCLL6FR
|
Chlorambucil
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Bendamustine hydrochloride + Chlorambucil
|
DCT7G19
|
Chlorambucil
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCZDC18
|
ER819762
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCYTVNO
|
ER819762
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCOIPV3
|
ER819762
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DC4X1OX
|
ER819762
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DC9C10M
|
ER819762
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCP3B3J
|
ER819762
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCIZ3VS
|
ER819762
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCT7AA4
|
ER819762
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCTRK6S
|
ER819762
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCKDSZ9
|
ER819762
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCE2HNU
|
ER819762
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCGEBSR
|
ER819762
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DC5IV2K
|
ER819762
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCFYZAL
|
ER819762
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Bendamustine hydrochloride + ER819762
|
DCWI0RX
|
ER819762
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Bendamustine hydrochloride + Pomalidomide
|
DC9TS0X
|
Pomalidomide
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bendamustine hydrochloride + Pomalidomide
|
DCVEOP8
|
Pomalidomide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Bendamustine hydrochloride + Aminolevulinic Acid Hydrochloride
|
DCWHGFZ
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Bendamustine hydrochloride + Aminolevulinic Acid Hydrochloride
|
DCJ5PU8
|
Aminolevulinic Acid Hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Bendamustine hydrochloride + Aminolevulinic Acid Hydrochloride
|
DCNF8PF
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bendamustine hydrochloride + Aminolevulinic Acid Hydrochloride
|
DCNPA37
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCMYOIZ
|
BIO-300
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DC8J3L7
|
BIO-300
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DC03HBQ
|
BIO-300
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCD71RM
|
BIO-300
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCT6R7A
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DC7RL2B
|
BIO-300
|
Glioma (Cell Line: SF-539)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCPD8LK
|
BIO-300
|
Glioma (Cell Line: SF-268)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCLWPYT
|
BIO-300
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCDD94C
|
BIO-300
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCZBXNF
|
BIO-300
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DC6LYSZ
|
BIO-300
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
BIO-300 + Bendamustine hydrochloride
|
DCKAVL0
|
BIO-300
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
BIO-300 + Bendamustine hydrochloride
|
DC695SI
|
BIO-300
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
BIO-300 + Bendamustine hydrochloride
|
DCWD8MG
|
BIO-300
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
BIO-300 + Bendamustine hydrochloride
|
DCTPF96
|
BIO-300
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
BIO-300 + Bendamustine hydrochloride
|
DCUUA2Q
|
BIO-300
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCPSVKC
|
BIO-300
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCTI5RQ
|
BIO-300
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DC6BYV9
|
BIO-300
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCP9C07
|
BIO-300
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCRXGG7
|
BIO-300
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCCIQPG
|
BIO-300
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DC9PG7A
|
BIO-300
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCYUDI0
|
BIO-300
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCZGLTG
|
BIO-300
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCEHGSK
|
BIO-300
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DC7UDR7
|
BIO-300
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCR1YRN
|
BIO-300
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCBZVS8
|
BIO-300
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCZIBN3
|
BIO-300
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCKW0CO
|
BIO-300
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCIADZT
|
BIO-300
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCNSDSE
|
BIO-300
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DCXU6RU
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Bleomycin + Bendamustine hydrochloride
|
DCPP50J
|
Bleomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bleomycin + Bendamustine hydrochloride
|
DC81S50
|
Bleomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Bleomycin + Bendamustine hydrochloride
|
DCEEO2N
|
Bleomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Bleomycin + Bendamustine hydrochloride
|
DCWYGNU
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DC0RFYO
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DC5VAYW
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DCQA5VI
|
Bleomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DCRCCB2
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DCGHJLD
|
Bleomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Bleomycin + Bendamustine hydrochloride
|
DCO8J32
|
Bleomycin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Busulfan + Bendamustine hydrochloride
|
DC4C8NM
|
Busulfan
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Busulfan + Bendamustine hydrochloride
|
DCIKJ4R
|
Busulfan
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DC2NGKO
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DC8SHCN
|
Cabazitaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DC3L6TL
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DCE1DZK
|
Cabazitaxel
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DCDINHQ
|
Cabazitaxel
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DCMRLFA
|
Cabazitaxel
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DCHXMTO
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DCOM78A
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DCWMHN9
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Cabazitaxel + Bendamustine hydrochloride
|
DC8WTQV
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Crizotinib + Bendamustine hydrochloride
|
DCD7E5R
|
Crizotinib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCARVJR
|
Crizotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DC66JG2
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCND7XR
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCYXNP1
|
Crizotinib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCHSBCF
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCOWTQS
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCQF5F2
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DC08QAN
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCC0ASU
|
Crizotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCOV40W
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCALOW4
|
Crizotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DCF338K
|
Crizotinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Crizotinib + Bendamustine hydrochloride
|
DC1MKAU
|
Crizotinib
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Crizotinib + Bendamustine hydrochloride
|
DC4ZWDW
|
Crizotinib
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Crizotinib + Bendamustine hydrochloride
|
DCTBIRV
|
Crizotinib
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Crizotinib + Bendamustine hydrochloride
|
DC7AFEA
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Dacarbazine + Bendamustine hydrochloride
|
DC6Z6UB
|
Dacarbazine
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCXYPQQ
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCNNBG3
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCP9CLU
|
Dacarbazine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCPV8UY
|
Dacarbazine
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCPAPNK
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCM33W2
|
Dacarbazine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCHOSW9
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DC2WFLZ
|
Dacarbazine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCH3V3M
|
Dacarbazine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Dacarbazine + Bendamustine hydrochloride
|
DCPJJF8
|
Dacarbazine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Dactinomycin + Bendamustine hydrochloride
|
DCQYY5T
|
Dactinomycin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Dactinomycin + Bendamustine hydrochloride
|
DC8SBH8
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Dactinomycin + Bendamustine hydrochloride
|
DCC1TFO
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Dasatinib + Bendamustine hydrochloride
|
DCSKINI
|
Dasatinib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DC1MHPS
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DC33B4K
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DCWV6AF
|
Dasatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DCCCZMD
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DCIMMNI
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DC0OBOK
|
Dasatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DCXFRCQ
|
Dasatinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Dasatinib + Bendamustine hydrochloride
|
DCEU2GZ
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Dexrazoxane + Bendamustine hydrochloride
|
DCM64IW
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Dexrazoxane + Bendamustine hydrochloride
|
DCDULKU
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Dexrazoxane + Bendamustine hydrochloride
|
DCPYG7F
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Dexrazoxane + Bendamustine hydrochloride
|
DC0RMID
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Dexrazoxane + Bendamustine hydrochloride
|
DCI6IP5
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Dexrazoxane + Bendamustine hydrochloride
|
DCC27QL
|
Dexrazoxane
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
DFN-15 + Bendamustine hydrochloride
|
DCOFVR0
|
DFN-15
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
DFN-15 + Bendamustine hydrochloride
|
DCQT2PG
|
DFN-15
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Docetaxel + Bendamustine hydrochloride
|
DCDCQ4G
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DC92KP7
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DCTYL2K
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DCW1O4S
|
Docetaxel
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DCWJOCV
|
Docetaxel
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DCG3ZX6
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DCC72KU
|
Docetaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Docetaxel + Bendamustine hydrochloride
|
DCCXMUB
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Docetaxel + Bendamustine hydrochloride
|
DC9JKE1
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Epirubicin + Bendamustine hydrochloride
|
DCUZ1XD
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Epirubicin + Bendamustine hydrochloride
|
DC4OY03
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Epirubicin + Bendamustine hydrochloride
|
DC4C3M0
|
Epirubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Epirubicin + Bendamustine hydrochloride
|
DCEZ6GD
|
Epirubicin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Epirubicin + Bendamustine hydrochloride
|
DCEJXAM
|
Epirubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Epirubicin + Bendamustine hydrochloride
|
DC4UQ6H
|
Epirubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Epirubicin + Bendamustine hydrochloride
|
DCLII6Z
|
Epirubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Epirubicin + Bendamustine hydrochloride
|
DCH44GA
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Epirubicin + Bendamustine hydrochloride
|
DC1C048
|
Epirubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Estramustine + Bendamustine hydrochloride
|
DCTSBC5
|
Estramustine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Estramustine + Bendamustine hydrochloride
|
DCU55XM
|
Estramustine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Fludarabine + Bendamustine hydrochloride
|
DCFVSS8
|
Fludarabine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Fludarabine + Bendamustine hydrochloride
|
DCLYNBA
|
Fludarabine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Fludarabine + Bendamustine hydrochloride
|
DC1QTIZ
|
Fludarabine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCN3658
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DC8H5Q7
|
FORMESTANE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCAEXDE
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCHI7XQ
|
FORMESTANE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCKJ12F
|
FORMESTANE
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCNESQ3
|
Gefitinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCYF2HB
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCFPASH
|
Gefitinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCODQEF
|
Gefitinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCAXV1D
|
Gefitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCYDKII
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCZ6CX4
|
Gefitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCLYOL6
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DC5SCKR
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DC1S8EJ
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCIZTYO
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCVAW8X
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCZK1UO
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCS54LL
|
Gefitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCXTKMZ
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCIKOJR
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCMD2ZI
|
Gefitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCPRFL5
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DC8DF14
|
Gefitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DC25F07
|
Gefitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DC7VQH9
|
Gefitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCU31IS
|
Gefitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCVS8RN
|
Gefitinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Gefitinib + Bendamustine hydrochloride
|
DCSHCJQ
|
Gefitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Gefitinib + Bendamustine hydrochloride
|
DCNCU2I
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Gefitinib + Bendamustine hydrochloride
|
DC53Z9K
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Hepzato + Bendamustine hydrochloride
|
DCV0C97
|
Hepzato
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Idarubicin + Bendamustine hydrochloride
|
DC9Y11G
|
Idarubicin
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Imatinib + Bendamustine hydrochloride
|
DCXUJ3Q
|
Imatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Imatinib + Bendamustine hydrochloride
|
DCT11YQ
|
Imatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Imatinib + Bendamustine hydrochloride
|
DCWPPOE
|
Imatinib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCNQXAJ
|
Indazole derivative 5
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCC2K7K
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCLKMEJ
|
Indazole derivative 5
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC5M0M4
|
Indazole derivative 5
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCPLF0E
|
Indazole derivative 5
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCTVHYH
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC7GXKQ
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCSHNL2
|
Indazole derivative 5
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCEELBR
|
Indazole derivative 5
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCFVNRS
|
Indazole derivative 5
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC7UVX4
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCGIG35
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCW73IU
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC5W7PV
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC9ABPF
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCE7U6R
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCAMH45
|
Indazole derivative 5
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCYQKVK
|
Indazole derivative 5
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCOF4HC
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCDS81C
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCH3PT9
|
Indazole derivative 5
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC90OUO
|
Indazole derivative 5
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCD2BDR
|
Indazole derivative 5
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
JNK-IN-8 + Bendamustine hydrochloride
|
DCXGYLZ
|
JNK-IN-8
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
JNK-IN-8 + Bendamustine hydrochloride
|
DCNQBGM
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
JNK-IN-8 + Bendamustine hydrochloride
|
DCLRRNL
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
JNK-IN-8 + Bendamustine hydrochloride
|
DCMU8JX
|
JNK-IN-8
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
JNK-IN-8 + Bendamustine hydrochloride
|
DCKOYSQ
|
JNK-IN-8
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
JNK-IN-8 + Bendamustine hydrochloride
|
DC3HV3Y
|
JNK-IN-8
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Lapatinib + Bendamustine hydrochloride
|
DCQUVH4
|
Lapatinib
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Lenalidomide + Bendamustine hydrochloride
|
DCFIXWL
|
Lenalidomide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Lenalidomide + Bendamustine hydrochloride
|
DCUBGTZ
|
Lenalidomide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Lenalidomide + Bendamustine hydrochloride
|
DCEWDML
|
Lenalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Lenalidomide + Bendamustine hydrochloride
|
DC6HT0C
|
Lenalidomide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Lenalidomide + Bendamustine hydrochloride
|
DC0DN5V
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Lenalidomide + Bendamustine hydrochloride
|
DC8MPZB
|
Lenalidomide
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Lenalidomide + Bendamustine hydrochloride
|
DCYRR5F
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Lenalidomide + Bendamustine hydrochloride
|
DC89WLA
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Lenalidomide + Bendamustine hydrochloride
|
DCWJ33M
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Lenalidomide + Bendamustine hydrochloride
|
DC8R2Z8
|
Lenalidomide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Lenalidomide + Bendamustine hydrochloride
|
DCSNZJ7
|
Lenalidomide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Lenalidomide + Bendamustine hydrochloride
|
DC2ISIN
|
Lenalidomide
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Letrozole + Bendamustine hydrochloride
|
DCEN74V
|
Letrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Letrozole + Bendamustine hydrochloride
|
DC36CTJ
|
Letrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Letrozole + Bendamustine hydrochloride
|
DC2D5K9
|
Letrozole
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Letrozole + Bendamustine hydrochloride
|
DC22L67
|
Letrozole
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Letrozole + Bendamustine hydrochloride
|
DC1BE6T
|
Letrozole
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Letrozole + Bendamustine hydrochloride
|
DCRBETP
|
Letrozole
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Letrozole + Bendamustine hydrochloride
|
DCFGD57
|
Letrozole
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Letrozole + Bendamustine hydrochloride
|
DCSCGV8
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
LIAROZOLE + Bendamustine hydrochloride
|
DCZHVIO
|
LIAROZOLE
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
LIAROZOLE + Bendamustine hydrochloride
|
DC6NY03
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Mechlorethamine + Bendamustine hydrochloride
|
DCRO0KI
|
Mechlorethamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Mechlorethamine + Bendamustine hydrochloride
|
DC9SI9I
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Mechlorethamine + Bendamustine hydrochloride
|
DCCAZX6
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Mechlorethamine + Bendamustine hydrochloride
|
DCT31IM
|
Mechlorethamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Mechlorethamine + Bendamustine hydrochloride
|
DC7YWAM
|
Mechlorethamine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Mechlorethamine + Bendamustine hydrochloride
|
DCOT6AK
|
Mechlorethamine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Mercaptopurine + Bendamustine hydrochloride
|
DC54BUW
|
Mercaptopurine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Methotrexate + Bendamustine hydrochloride
|
DCWYH01
|
Methotrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Nilotinib + Bendamustine hydrochloride
|
DCTLU6G
|
Nilotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Nilotinib + Bendamustine hydrochloride
|
DCIBU0E
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Nilotinib + Bendamustine hydrochloride
|
DCT6O5R
|
Nilotinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Nilotinib + Bendamustine hydrochloride
|
DCDEXJ6
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Picoplatin + Bendamustine hydrochloride
|
DCIN20I
|
Picoplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Picoplatin + Bendamustine hydrochloride
|
DCDKYNK
|
Picoplatin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Plicamycin + Bendamustine hydrochloride
|
DCL01FG
|
Plicamycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
PMID28460551-Compound-2 + Bendamustine hydrochloride
|
DCT4OB4
|
PMID28460551-Compound-2
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
PMID28870136-Compound-43 + Bendamustine hydrochloride
|
DC1Q9N0
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28870136-Compound-43 + Bendamustine hydrochloride
|
DCZ5HNP
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Pralatrexate + Bendamustine hydrochloride
|
DCEEQZ1
|
Pralatrexate
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Pralatrexate + Bendamustine hydrochloride
|
DC4YKOX
|
Pralatrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Raloxifene + Bendamustine hydrochloride
|
DC8B9O3
|
Raloxifene
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DCUCIMB
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DC2SRB3
|
Raloxifene
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DCZ9IJD
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DCG0ONS
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DCP7VZ5
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Raloxifene + Bendamustine hydrochloride
|
DCJP7GL
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Romidepsin + Bendamustine hydrochloride
|
DC6SL1Z
|
Romidepsin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Romidepsin + Bendamustine hydrochloride
|
DC529HP
|
Romidepsin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCYIXAC
|
Ruxolitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCV8UUE
|
Ruxolitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC0MQNV
|
Ruxolitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC72W88
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCESEXU
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCBJ8PA
|
Ruxolitinib
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC05FN6
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCL08H7
|
Ruxolitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCD9VLH
|
Ruxolitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC9QSHE
|
Ruxolitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCTR5AW
|
Ruxolitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
SCH 727965 + Bendamustine hydrochloride
|
DC5RF1I
|
SCH 727965
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Sirolimus + Bendamustine hydrochloride
|
DCA06DW
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Sirolimus + Bendamustine hydrochloride
|
DCJY3GB
|
Sirolimus
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Taxol + Bendamustine hydrochloride
|
DCDMGYV
|
Taxol
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Terameprocol + Bendamustine hydrochloride
|
DCEBZGK
|
Terameprocol
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Thioguanine + Bendamustine hydrochloride
|
DCJSRS2
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Thioguanine + Bendamustine hydrochloride
|
DCV92UI
|
Thioguanine
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Thioguanine + Bendamustine hydrochloride
|
DCYQHPS
|
Thioguanine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Thioguanine + Bendamustine hydrochloride
|
DCVU5CQ
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Thioguanine + Bendamustine hydrochloride
|
DC91AMB
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Thioguanine + Bendamustine hydrochloride
|
DCZ6JW7
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Thioguanine + Bendamustine hydrochloride
|
DCI3LKH
|
Thioguanine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Thioguanine + Bendamustine hydrochloride
|
DCL0FQG
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Thioguanine + Bendamustine hydrochloride
|
DC16ATG
|
Thioguanine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Thioguanine + Bendamustine hydrochloride
|
DCV2WBN
|
Thioguanine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCOMDCG
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Topotecan + Bendamustine hydrochloride
|
DCZ2LET
|
Topotecan
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCLE8SJ
|
Topotecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DC5GR4B
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCAW70D
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCN8KK1
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCWGMSR
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCVIIS9
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCS40FU
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DC0HVFL
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCVE8UK
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCK13UJ
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DC4NV8E
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCQWJH8
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCUR3GY
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DC64CTI
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Topotecan + Bendamustine hydrochloride
|
DCOX7RI
|
Topotecan
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DCXYEUB
|
Trifluridine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Trifluridine + Bendamustine hydrochloride
|
DCHL8DC
|
Trifluridine
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Trifluridine + Bendamustine hydrochloride
|
DC29K16
|
Trifluridine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Trifluridine + Bendamustine hydrochloride
|
DCLBH0L
|
Trifluridine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Trifluridine + Bendamustine hydrochloride
|
DCOJ6RO
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Trifluridine + Bendamustine hydrochloride
|
DCCEOWY
|
Trifluridine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DC5VYZV
|
Trifluridine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DC35VZ3
|
Trifluridine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DCWKKVY
|
Trifluridine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DCJZG1Q
|
Trifluridine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DCNCPRC
|
Trifluridine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Trifluridine + Bendamustine hydrochloride
|
DCZTP1U
|
Trifluridine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCUDGLH
|
Uracil mustard
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCL4PCO
|
Uracil mustard
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCL956D
|
Uracil mustard
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCNWNJG
|
Uracil mustard
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCSHQB6
|
Uracil mustard
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCNFXFN
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DC5MI9A
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCYP0H1
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCT0K8M
|
Uracil mustard
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DCW04KT
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Uracil mustard + Bendamustine hydrochloride
|
DC8529N
|
Uracil mustard
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Valrubicin + Bendamustine hydrochloride
|
DC5ET3S
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Valrubicin + Bendamustine hydrochloride
|
DC6PF4D
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Valrubicin + Bendamustine hydrochloride
|
DCYO7OA
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Valrubicin + Bendamustine hydrochloride
|
DCNIUN0
|
Valrubicin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCGSGJY
|
Vandetanib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Vandetanib + Bendamustine hydrochloride
|
DC8IE6B
|
Vandetanib
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Vandetanib + Bendamustine hydrochloride
|
DCTE6CM
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vandetanib + Bendamustine hydrochloride
|
DCLDPIA
|
Vandetanib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DC2A9TW
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCO5G5L
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DC4N2LB
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCGTLX4
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCQHST9
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCXUNAY
|
Vandetanib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCPF9VR
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DC8B37G
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DC99CIK
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCYC2Q9
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCG0Y4M
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCKR8FU
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DC50HLW
|
Vandetanib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCB2I4F
|
Vandetanib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DC5UAN4
|
Vandetanib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCKZCIB
|
Vandetanib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCTMSZ0
|
Vandetanib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vandetanib + Bendamustine hydrochloride
|
DCIM4G6
|
Vandetanib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCRFXZX
|
Vemurafenib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCQ0BEV
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vemurafenib + Bendamustine hydrochloride
|
DC7GC4Y
|
Vemurafenib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DC66MDC
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCBG4ID
|
Vemurafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DC7ULW5
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCZ7S1A
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCXU1JN
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCX1M0V
|
Vemurafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCR3OTO
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCGXDYX
|
Vemurafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCMLDX1
|
Vemurafenib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCTA3VG
|
Vemurafenib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCHKEHV
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Bendamustine hydrochloride
|
DCQPX0L
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vincristine + Bendamustine hydrochloride
|
DCU3AEL
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vincristine + Bendamustine hydrochloride
|
DCS8RZT
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Vincristine + Bendamustine hydrochloride
|
DC23VSG
|
Vincristine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vincristine + Bendamustine hydrochloride
|
DC0DVLK
|
Vincristine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vincristine + Bendamustine hydrochloride
|
DC9EDSH
|
Vincristine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Vincristine + Bendamustine hydrochloride
|
DCW3TZH
|
Vincristine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Vinflunine + Bendamustine hydrochloride
|
DCB1X1F
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Vinflunine + Bendamustine hydrochloride
|
DCE0WQ7
|
Vinflunine
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Vinflunine + Bendamustine hydrochloride
|
DCI0JSG
|
Vinflunine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Vinflunine + Bendamustine hydrochloride
|
DC57VSV
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Vinflunine + Bendamustine hydrochloride
|
DC0J9T2
|
Vinflunine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vinflunine + Bendamustine hydrochloride
|
DC081Y2
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vinflunine + Bendamustine hydrochloride
|
DC6XJNN
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCF5765
|
Vismodegib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Vismodegib + Bendamustine hydrochloride
|
DCU9ZY3
|
Vismodegib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DC0M10M
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCW0O6J
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCLTX6X
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCG3C2Q
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCKPWF0
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCJAHVY
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCLODJH
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCTDV4X
|
Vismodegib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCD8724
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCIQKZ4
|
Vismodegib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCPRKTY
|
Vismodegib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DC96K8F
|
Vismodegib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCQ0Y7M
|
Vismodegib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DC23NG6
|
Vismodegib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vismodegib + Bendamustine hydrochloride
|
DCO8VBN
|
Vismodegib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
